study_start,study_end,eligible_patients,treated_patients,treated_paxlovid,treated_sotrovimab,treated_remdesivir,treated_molnupiravir,treated_casirivimab,high_risk_cohort_2plus,high_risk_cohort_lower,high_risk_cohort_upper
2021-12-11,2022-10-07,135970,32650,10850,15090,60,6600,50,22380,1,7
